Nexus Pharmaceuticals has received clearance from the Food and Drug Administration for methylene blue injection, which is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia.
“We are pleased to strengthen the supply of an AP-rated and TIAA compliant methylene blue Injection,” said Sridhar Desikan, chief scientific officer at Nexus Pharmaceuticals. “The addition of methylene blue to our portfolio further emphasizes Nexus’ persistent ambition to provide life-saving medicine to those who need it most.”
Methylene blue injection, 50 mg/10 ml (5 mg/ml) (0.5%) will be available in cartons of five 10 ml single-dose vials.